Who are Addyi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): XANOMELINE, Remeron, (S)-Remoxipride, Merital, Desyrel, Dulcotil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flibanserin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Addyi — Competitive Intelligence Brief

Addyi (FLIBANSERIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed 5-hydroxytryptamine receptor 1A Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Addyi (FLIBANSERIN) — Sprout Pharms. Addyi works by increasing the levels of neurotransmitters dopamine, serotonin, and norepinephrine in the brain, which helps to regulate sexual desire.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Addyi TARGET	FLIBANSERIN	Sprout Pharms	marketed		5-hydroxytryptamine receptor 1A	2015-01-01
XANOMELINE	XANOMELINE		marketed		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A	2024-01-01
Remeron	mirtazapine	Generic (originally Organon/MSD)	marketed	NaSSA (Noradrenergic and specific serotonergic antidepressant)	5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C	1996-06-14
(S)-Remoxipride	REMOXIPRIDE		marketed	remoxipride	D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A	1990-01-01
Merital	NOMIFENSINE		marketed	nomifensine	Hemoglobin HbA, Myeloperoxidase, 5-hydroxytryptamine receptor 1A	1984-01-01
Desyrel	trazodone	Generic (originally Angelini/Pragmaten)	marketed	SARI (Serotonin antagonist and reuptake inhibitor)	HLA class I histocompatibility antigen, A-3 alpha chain, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A	1981-12-24
Dulcotil	SULOCTIDIL		marketed	suloctidil	Adenosine receptor A3, Substance-K receptor, 5-hydroxytryptamine receptor 1A	1979-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Addyi — Competitive Intelligence Brief. https://druglandscape.com/ci/flibanserin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab